Clinical Trial Detail

NCT ID NCT03689699
Title Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Charles G. Drake
Indications

prostate cancer

Therapies

BMS-986253 + Degarelix + Nivolumab

Degarelix + Nivolumab

Age Groups: adult

No variant requirements are available.